MedTrace Logo

Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer

NCT03301701 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-12-01

No results posted yet for this study

Summary

Patients with hormone sensitive oligometastatic prostate cancer (≤ 5 metastatic tumours outside of regional pelvic nodes with no more than 3 in any organ system) and no previous treatment to prostate will be treated with intermittent androgen deprivation therapy +/- chemotherapy, stereotactic radiotherapy to all metastases, and either radical prostatectomy or radiotherapy.

Conditions

  • Hormone Sensitive Oligometastatic Prostate Cancer

Interventions

PROCEDURE

Radical prostatectomy

Radical prostatectomy

RADIATION

HDR (19Gy) or SBRT (35-40Gy)

Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT

Sponsors & Collaborators

  • Dr. Patrick Cheung

    lead OTHER

Principal Investigators

  • Patrick Cheung · Sunnybrook Health Sciences Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2019-05-30
Completion
2019-05-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03301701 on ClinicalTrials.gov